Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of SHR-A2102 alone or in combination in advanced solid tumors
CTR20241520Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-A2102, adebrelimab and disitamab vedotin in Nonhematologic neoplasms (3 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Recommended phase 2 dose (RP2D), Adverse event incidence and severity and 1 more. Started May 2024; status: active.
02
Drugs
SHR-A2102adebrelimabdisitamab vedotin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241520.